PitchSend

argenx SE Investor Day Presentation Deck

Building a Leading Immunology Company argenx Committed to our Patients and their Communities Rooted in Science through our IIP Enviable Immunology Pipeline Global autoimmune market has surpassed $150B Efgartigimod available globally Vibrant neuromuscular, hematology and skin franchises Efgartigimod in 15 indications (commercial or development) ARGX-117 in multiple late-stage trials Proof-of-concept demonstrated with ARGX-119 New asset each year from IIP We believe the future belongs to those who collaborate best 14

View entire presentation